Abstract
In 2007, the US FDA recommended that pharmaceutical companies and CROs conduct incurred sample reanalysis (ISR) following the analysis of study samples using validated methods. Between January 2008 and Deccember 2009, over 250 separate analytes were tested for ISR in our laboratory (a bioanalytical CRO). Among these, nine analytes initially failed for ISR. While thorough investigations were conducted to identify the root cause of ISR failure for each study, these investigations were often painfully tedious and very costly, both financially and in terms of project timelines. In this paper, three representative studies are presented to showcase the detailed investigation processes, methodologies and final conclusions of the ISR investigations. Additionally, all nine ISR failures are analyzed to identify trends or common elements of the studies or methods that might help identify potential problems before they occur. Furthermore, suggestions and recommendations to minimize future ISR failures are provided.
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
Bibliography
- 1 Shah VP, Midha KK, Dighe S et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. Pharm. Res.9,588–592 (1992).Crossref, Google Scholar
- 2 US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for the Industry: Bioanalytical Method Validation. Rockville, MD, USA, May 2001.Google Scholar
- 3 Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J.9,E30–E42 (2007).▪▪ American Association of Pharmaceutical Scientists (AAPS)/US FDA Workshop Conference Report. First official publication to propose the use of incurred sample reanalysis (ISR) for regulated bioanalysis.Crossref, Google Scholar
- 4 Rocci ML, Devanarayan V, Haughey DB et al. Confirmatory reanalysis of incurred bioanalytical samples. AAPS J.9(3),E336–E343 (2007).▪▪ First follow-up publication of 3rd AAPS Workshop Report solely addressing various ISR issues.Crossref, Medline, CAS, Google Scholar
- 5 Fast DM, Kelley M, Viswanathan C et al. AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples-implications of crystal city recommendations. AAPS J.11(2),238–241 (2009).▪▪ Second follow-up publication of 3rd AAPS Workshop Report in which more practical guidance for ISR were presented.Crossref, Medline, Google Scholar
- 6 Timmerman P, Luedtke S, Amsterdam PV et al. Incurred sample reproducibility, views and recommendations by the European Bioanalysis Forum. Bioanalysis1(6),1049–1056 (2009).▪ Additional international perspective on the topic of ISR.Link, CAS, Google Scholar
- 7 Jemal M, Zheng O, Xia YQ. Systematic LC–MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. Biomed. Chromatogr.24,2–19 (2009).Crossref, Google Scholar
- 101 Health Canada. Conduct and analysis of bioavailability and bioequivalence studies part B: oral modified release formulations. www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/bio-b-eng.phpGoogle Scholar
- 102 Health Canada. Notice to industry-removal of requirement for 15% random replicate samples notice affecting guideline A and guidance B requirement. www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/15rep-eng.phpGoogle Scholar
